A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Fedratinib (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2021 New trial record